Business
Aurora and MedReleaf Australia Launch IndiMed Tempo 26, Further Strengthening Product Offerings for Medical Cannabis Patients
Aurora and MedReleaf Australia Launch IndiMed Tempo 26, Further Strengthening Product Offerings f...
About this update from Aurora Cannabis Inc.
[{"type":"text","content":"\n \n \n \n Aurora and MedReleaf Australia Launch IndiMed Tempo 26, Further Strengthening Product Offerings for Medical Cannabis Patients\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n Available through MedReleaf's Concession Scheme, doctors and patients will have more\n \n \n \n \n \n freedom in choosing their cannabis medication\n \n \n \n \n \n \n EDMONTON, AB\n \n \n ,\n \n \n April 12, 2023\n \n \n /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, and MedReleaf Australia today announced the launch of IndiMed Tempo 26, a range of new higher THC dried cannabis products for qualified patients under the MedReleaf Concession Scheme (MCS). Tempo 26 will add to the portfolio of products available, giving doctors the ability to prescribe from a wider range of options for medical cannabis patients.\n \n \n \n \n \n \n \n \n \n \"We are proud to further expand the variety of high-quality medical cannabis products that Australian patients can access through the MedReleaf Concession Scheme, and with the addition of Tempo 26, doctors and patients now have more control and choice about their medical cannabis treatment than ever before,\" says\n \n Miguel Martin\n \n , CEO of Aurora Cannabis. \"We are strongly committed to our patient-first approach to cannabis and ensuring access to medical patients, in\n \n Australia\n \n , and around the world.\"\n \n \n The MCS was developed by MedReleaf Australia and Aurora to provide high-quality products and enhance patient access to medical cannabis, which is not covered by the Pharmaceutical Benefits Scheme (PBS). Through the MCS, patients can access compassionate pricing, specifically for those with Pensioner Concession Cards, Commonwealth Seniors Health Cards, Health Care Cards, and Veterans Cards (DVA).\n \n \n \"Through the investment of Aurora and MedReleaf Australia, we have been able to provide heavily discounted products via our MedReleaf Concession Scheme, which widens the choice for pres...